HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Natura Bisse Cytokines skin care treatments with Epidermal Growth Factor rolling out.

This article was originally published in The Rose Sheet

Executive Summary

NATURA BISSE CYTOKINES "CELL RENEWAL" LINE TARGETING "MATURE" SKIN that has lost elasticity due to damage from factors such as the sun, aging and the environment, according to the San Antonio, Tex.-based prestige skin care company. The three-SKU line is "especially appropriate" for consumers 40 and older who "desire firming and repairing benefits," Natura Bisse said. Products offer consumers "renewed texture and suppleness" and "a visible improvement in firmness and elasticity," the firm claims. Natura Bisse is positioning the line for all skin types and for customers with good complexions as well as severely damaged skin. The collection will be available in mid-December exclusively in all Neiman Marcus stores, as well as in select spas in areas not served by Neiman's. The line will also be launched in Bergdorf Goodman's in New York City.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004930

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel